Skip to Content Facebook Feature Image

The Estée Lauder Companies and the Breast Cancer Research Foundation Launch Largest Global Research Initiative on Breast Cancer in Younger Women

Business

The Estée Lauder Companies and the Breast Cancer Research Foundation Launch Largest Global Research Initiative on Breast Cancer in Younger Women
Business

Business

The Estée Lauder Companies and the Breast Cancer Research Foundation Launch Largest Global Research Initiative on Breast Cancer in Younger Women

2026-09-23 20:30 Last Updated At:20:40

NEW YORK--(BUSINESS WIRE)--Sep 23, 2026--

The Estée Lauder Companies today announced a new five-year commitment to the Breast Cancer Research Foundation to establish the Global Research Initiative on Breast Cancer in Younger Women. This first-of-its-kind research coalition will address the alarming global rise in breast cancer diagnoses among younger women, building on more than three decades of partnership between The Estée Lauder Companies and the Breast Cancer Research Foundation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260923337773/en/

The $15 million commitment from The Estée Lauder Companies Charitable Foundation is designed to confront an urgent and significantly underfunded need. Diagnoses among women under age 45 increased by 11 percent from 2012 to 2022, 1 while an estimated only 0.6 percent of breast cancer research funding since 2020 has focused on younger women. Breast cancer in younger women is more likely to be diagnosed at a later stage and to behave aggressively, with women diagnosed before age 40 nearly 40 percent more likely to die from the disease. 2

Through the largest coordinated global research program of its kind, scientists from around the world will work together to investigate the biological factors of early-onset breast cancer. Their research will seek to generate critical new insights and improve approaches to risk prediction, prevention, early detection, and treatment.

Accelerating a New Era of Breast Cancer Research

“The Estée Lauder Companies has a longstanding commitment to advancing breast cancer research, and I know my mother, Evelyn H. Lauder, would be so proud to see us carry her vision forward. She believed deeply in the power of research to change and ultimately save lives. Through this donation, we can expand our understanding of breast cancer in younger women, an area where there is still much to learn. I am grateful to the brilliant scientific researchers whose curiosity, dedication, and discoveries continue to bring us closer to our shared goal of a world free from breast cancer,” said William P. Lauder, Chair, Board of Directors, The Estée Lauder Companies, and Co-Chair, the Breast Cancer Research Foundation.

“For more than 30 years, The Estée Lauder Companies has been deeply committed to helping create a breast cancer-free world. That commitment is rooted in who we are: a company founded by a woman and serving millions of women around the world. It also reflects our enduring belief in the power of research, partnership, and collective action to improve and save lives. As diagnoses rise among younger women, we have a responsibility to act with urgency. We are proud to build on our longstanding partnership with the Breast Cancer Research Foundation and help lead a new era of global collaboration to improve outcomes for generations of women and families,” said Stéphane de La Faverie, President and Chief Executive Officer, The Estée Lauder Companies and President, The Estée Lauder Companies Charitable Foundation.

The inaugural grant will launch the initial phase of research focused on the biology of breast cancer among younger women. It will examine the mechanisms that drive early-onset breast cancer, laying the foundation for accelerating the path from laboratory discovery to patient care. By connecting scientists across countries, institutions, and disciplines, the initiative is designed to help break down traditional research silos, accelerate the exchange of knowledge, and establish a stronger scientific foundation for progress. Insights from its initial phase will help shape subsequent areas of investigation, with the goal of translating discovery into meaningful advances for younger women facing breast cancer around the world.

“The Breast Cancer Research Foundation has always been at the vanguard of addressing persistent challenges in the disease and is proud to have already been advancing the largest body of research in younger women. The alarming rise in incidence among this demographic warrants a global response to fund the scientists who are in a race to find answers. We are deeply grateful to our partners at The Estée Lauder Companies, whose groundbreaking donation makes this unprecedented global initiative possible and creates an opportunity to fundamentally advance our understanding of the disease and improve outcomes for younger patients,” said Donna McKay, President and CEO of the Breast Cancer Research Foundation.

Building on More Than 30 Years of Partnership and Progress

The Breast Cancer Research Foundation was founded in 1993 by Evelyn H. Lauder, who co-created the iconic pink ribbon and launched The Estée Lauder Companies’ Breast Cancer Campaign. Since then, The Estée Lauder Companies and its Charitable Foundation have funded more than $123 million in lifesaving breast cancer research through The Breast Cancer Research Foundation, supporting more than 400 research grants. Together, the organizations have helped build a global model for advancing scientific discovery and translating research into better care. Their partnership has also supported the largest global study of breast cancer in Black women, significantly advancing scientific understanding of the factors contributing to disparities in breast cancer outcomes.

Over the past 30 years, breast cancer deaths have declined by 44 percent, 3 while treatment options have expanded from a single targeted treatment in 1993 to more than 30 today, demonstrating the extraordinary progress that sustained investment in research and precision medicine can make possible.

The Global Research Initiative on Breast Cancer in Younger Women marks the next chapter of this shared legacy. By directing unprecedented global scientific attention and resources toward breast cancer in younger women, The Estée Lauder Companies and the Breast Cancer Research Foundation aim to close critical gaps in knowledge, accelerate the pace of discovery, and help create a future in which every woman—regardless of her age—has the best possible chance to prevent, detect, treat and survive breast cancer.

About The Estée Lauder Companies

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers and sellers of quality skin care, makeup, fragrance and hair care products, and is a steward of luxury and prestige brands globally. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, the DECIEM family of brands, including The Ordinary, NIOD, Avestan and Loopha, and Balmain Beauty.

About The Estée Lauder Companies Charitable Foundation

The Estée Lauder Companies Charitable Foundation (ELCCF) is the global philanthropic arm of The Estée Lauder Companies, a leader in prestige beauty. Turning The Estée Lauder Companies’ and Mrs. Estée Lauder’s legacy into action, the ELCCF supports nonprofit organizations that enable women and girls to thrive and advance through the transformative power of health, education, and entrepreneurship. The Foundation invests in programs worldwide that strengthen career readiness, workforce participation, and leadership development for women and girls, and supports scientists and practitioners advancing breakthroughs in breast cancer and women’s health.

About the Breast Cancer Research Foundation

Breast cancer is a complex disease with no simple solution. Research is the key to stopping it in its tracks. Founded in 1993 by Evelyn H. Lauder, BCRF is the largest private funder of breast cancer research in the world. By investing in the best minds in science to examine every aspect of the disease from prevention to metastasis—and fostering cross-disciplinary collaboration—BCRF is accelerating the entire field and moves us closer to the answers we urgently need to be the end of breast cancer. Learn more and get involved at BCRF.org.

Citations:

[1] Centers for Disease Control and Prevention. (2025, August 15). Breast cancer among women younger than 45. U.S. Cancer Statistics.
[2] Gnerlich, J. L., Deshpande, A. D., Jeffe, D. B., Sweet, A., White, N., & Margenthaler, J. A. (2009). Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. Journal of the American College of Surgeons , 208 (3), 341–347.
[3] Printz, C., & McDowell, S. (2024, October 2). Breast cancer incidence still rises and death rate still declines. American Cancer Society.

ELC-C

The Estée Lauder Companies and the Breast Cancer Research Foundation Launch Largest Global Research Initiative on Breast Cancer in Younger Women

The Estée Lauder Companies and the Breast Cancer Research Foundation Launch Largest Global Research Initiative on Breast Cancer in Younger Women

LOS ANGELES, Calif.--(BUSINESS WIRE)--Sep 27, 2026--

Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future,” “FF,” or the “Company”), a California-based global Embodied AI (“EAI”) ecosystem company, today announced that this week’s Investor Weekly Report from FF Founder and Global CEO YT Jia, originally scheduled for September 27, has been rescheduled for September 28, one day later than planned.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260927266984/en/

Additionally, the Company has invited 10 global partners to participate in its FF EAI “Built in USA” Upstream & Downstream Business Partner Conference Part Two. Supplier representatives, including MetaSense Technology USA, ENCOS, and NexCOBOT, will share insights on global manufacturing and supply chain resources, core hardware such as robot joint modules, and open robotics control and functional safety platforms.

The full conference video will go live at 5:00 p.m. PDT on September 29 at www.ff.com.

ABOUT FARADAY FUTURE

Founded in 2014, Faraday Future (FF) is a U.S.-based Physical AI ecosystem company dedicated to reshaping the future of robotics and mobility solutions through AI innovation and technologies. FF focuses on two major product strategies within the Embodied AI (EAI) robotics business: EAI humanoid and bionic robots, and EAI automotive-focused robots. By building a "Four-Core Full-Stack AI" ecosystem of EAI Brain and Developer Platform, EAI Devices, Industry Productivity Solutions and EAI Data Factory, FF aims to create an evolutionary flywheel: scaled device delivery, data collection and training, continuous evolution of the EAI Brain, stronger product capability, and even larger-scale delivery and deployment. Through this flywheel, FF seeks to maximize its commercial value and lead to the advancement of Physical AI. For more information, please visit Faraday Future's official website: https://www.ff.com/

FORWARD LOOKING STATEMENTS

Important factors, that may affect actual results or outcomes include, among others: the Company’s ability to continue as a going concern and improve its liquidity and financial position; the Company’s ability to pay its outstanding obligations, which it currently lacks; the availability of sufficient share capital to meet its current obligations and execute on its strategy; the willingness of convertible debt investors to fund the Company; demand for the Company’s robotics products; the ability of B2B preorder companies to locate customers to purchase our robotics products, on which their nonbinding preorders substantially depend; competition in the robotics industry, which includes companies with far superior experience, funding and name recognition; the ability of the Company to build an EAI education ecosystem that serves both the B2C consumer market and the B2B institutional education market; the acceptance by teachers and students of the Company’s robotics products in the education market; the ability of the Company to expand into additional markets for its robotics products; the Company’s reliance on a single OEM for most of its robotics products; the Company’s reliance on Chinese OEMs for all of its robotics products; the possibility of the federal government banning imports of Chinese robotics products; the Company’s ability to get the planned robotics products to comply with all applicable U.S. rules and regulations; the ability of the robotics OEM to timely supply robotics to the Company; tariff uncertainty for imported products, particularly from China; demand from automobile dealers for robotics products; the Company's ability to homologate FX vehicles for sale; the Company’s ability to secure the necessary funding to execute on the FX strategy, which is substantial; the Company’s ability to secure an occupancy certificate covering all of its Hanford facility; the Company's ability to remediate its material weaknesses in internal control over financial reporting and the risks related to the restatement of previously issued consolidated financial statements; the Company’s limited operating history and the significant barriers to growth it faces; the Company’s history of substantial losses and expectation of continued losses; the success of the Company’s payroll expense reduction plan; the Company’s ability to execute on its plans to develop and market its vehicles and the timing of these development programs; the Company’s estimates of the size of the markets for its vehicles and cost to bring those vehicles to market; the rate and degree of market acceptance of the Company’s vehicles; the Company’s ability to cover future warranty claims; the success of other competing manufacturers; the performance and security of the Company’s vehicles; current and potential litigation involving the Company; the Company’s ability to receive funds from, satisfy the conditions precedent of and close on the various financings described elsewhere by the Company; the result of future financing efforts, the failure of any of which could result in the Company seeking protection under the Bankruptcy Code; the Company’s indebtedness; the Company’s ability to use its “at-the-market” program; insurance coverage; general economic and market conditions impacting demand for the Company’s products; potential negative impacts of a reverse stock split; potential cost, headcount and salary reduction actions may not be sufficient or may not achieve their expected results; circumstances outside of the Company's control, such as natural disasters, climate change, health epidemics and pandemics, terrorist attacks, and civil unrest; risks related to the Company's operations in China; the success of the Company's remedial measures taken in response to the Special Committee findings; the Company’s dependence on its suppliers and contract manufacturer; the Company's ability to develop and protect its technologies; the Company's ability to protect against cybersecurity risks; and the ability of the Company to attract and retain employees, any adverse developments in existing legal proceedings or the initiation of new legal proceedings, and volatility of the Company’s stock price. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 13, 2026; the quarter ended March 31, 2026, filed with the SEC on May 14, 2026, and Form 10-K filed with the SEC on March 31, 2026, and other documents filed by the Company from time to time with the SEC.

Faraday Future Announces This Week’s Investor Weekly Report From YT Jia Has Been Rescheduled to September 28; FF EAI “Built in USA” Upstream & Downstream Business Partner Conference Part Two to Be Held September 29

Faraday Future Announces This Week’s Investor Weekly Report From YT Jia Has Been Rescheduled to September 28; FF EAI “Built in USA” Upstream & Downstream Business Partner Conference Part Two to Be Held September 29

Recommended Articles